ClinicalTrials.Veeva

Menu

Total Hip Replacement Study With XRP4563 (Enoxaparin Sodium)

Sanofi logo

Sanofi

Status and phase

Completed
Phase 3

Conditions

Arthroplasty, Replacement, Hip

Treatments

Drug: Enoxaparin sodium

Study type

Interventional

Funder types

Industry

Identifiers

NCT00349180
EFC6770

Details and patient eligibility

About

This study is performed to confirm the optimal dose for THR (total hip replacement).

Sex

All

Ages

20+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients undergoing elective primary THR (total hip replacement) surgery

Exclusion criteria

  • Patient with risk of clinical significant bleeding

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems